These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Molecular Basis of Coronavirus Virulence and Vaccine Development. Enjuanes L; Zuñiga S; Castaño-Rodriguez C; Gutierrez-Alvarez J; Canton J; Sola I Adv Virus Res; 2016; 96():245-286. PubMed ID: 27712626 [TBL] [Abstract][Full Text] [Related]
7. SARS and MERS: recent insights into emerging coronaviruses. de Wit E; van Doremalen N; Falzarano D; Munster VJ Nat Rev Microbiol; 2016 Aug; 14(8):523-34. PubMed ID: 27344959 [TBL] [Abstract][Full Text] [Related]
8. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. Liu J; Zheng X; Tong Q; Li W; Wang B; Sutter K; Trilling M; Lu M; Dittmer U; Yang D J Med Virol; 2020 May; 92(5):491-494. PubMed ID: 32056249 [TBL] [Abstract][Full Text] [Related]
9. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. Kindler E; Thiel V; Weber F Adv Virus Res; 2016; 96():219-243. PubMed ID: 27712625 [TBL] [Abstract][Full Text] [Related]
10. Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. Halaji M; Farahani A; Ranjbar R; Heiat M; Dehkordi FS Infez Med; 2020 Jun; 28(suppl 1):6-17. PubMed ID: 32532933 [TBL] [Abstract][Full Text] [Related]
12. Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus. Sutton TC; Subbarao K Virology; 2015 May; 479-480():247-58. PubMed ID: 25791336 [TBL] [Abstract][Full Text] [Related]
13. The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection. Fehr AR; Channappanavar R; Jankevicius G; Fett C; Zhao J; Athmer J; Meyerholz DK; Ahel I; Perlman S mBio; 2016 Dec; 7(6):. PubMed ID: 27965448 [TBL] [Abstract][Full Text] [Related]
14. Modulation of the immune response by Middle East respiratory syndrome coronavirus. Shokri S; Mahmoudvand S; Taherkhani R; Farshadpour F J Cell Physiol; 2019 Mar; 234(3):2143-2151. PubMed ID: 30146782 [TBL] [Abstract][Full Text] [Related]
15. Inflammation, Thrombosis, and Destruction: The Three-Headed Cerberus of Trauma- and SARS-CoV-2-Induced ARDS. Lupu L; Palmer A; Huber-Lang M Front Immunol; 2020; 11():584514. PubMed ID: 33101314 [TBL] [Abstract][Full Text] [Related]
16. Antivirals for Respiratory Viral Infections: Problems and Prospects. Liu Q; Zhou YH; Ye F; Yang ZQ Semin Respir Crit Care Med; 2016 Aug; 37(4):640-6. PubMed ID: 27486742 [TBL] [Abstract][Full Text] [Related]
17. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN- Anjum FR; Anam S; Abbas G; Mahmood MS; Rahman SU; Goraya MU; Abdullah RM; Luqman M; Ali A; Akram MK; Chaudhry TH Viral Immunol; 2021 Jun; 34(5):321-329. PubMed ID: 33181057 [TBL] [Abstract][Full Text] [Related]
18. Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species. Smits SL; van den Brand JM; de Lang A; Leijten LM; van Ijcken WF; van Amerongen G; Osterhaus AD; Andeweg AC; Haagmans BL J Virol; 2011 May; 85(9):4234-45. PubMed ID: 21325418 [TBL] [Abstract][Full Text] [Related]
19. What are our pharmacotherapeutic options for MERS-CoV? Al-Tawfiq JA; Memish ZA Expert Rev Clin Pharmacol; 2014 May; 7(3):235-8. PubMed ID: 24580083 [TBL] [Abstract][Full Text] [Related]